Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
46/100
The number of people living with dementia worldwide is projected to reach 150 million by 2050, making prevention a crucial priority for health services.
Why it matters
In 282,712 UK Biobank participants, the risk of dementia varied with the type and timing of chronic conditions accumulated over life: cardiometabolic conditions before age 55, and mental health and neurovascular conditions from 55 to 70, were most strongly linked to dementia risk. This identifies possible risk factors and windows for prevention but does not test any intervention.
-
Key Points Regardless of race and ethnicity, older adults with kidney failure residing in or receiving care at dialysis facilities located in high-segregation neighborhoods were at a 1.63-fold and 1.53-fold higher risk of dementia diagnosis, respectively.
Why it matters
Among older adults with kidney failure, living in or getting dialysis care in highly segregated neighborhoods was linked to a higher risk of a dementia diagnosis. This is an observational look at where people live and their diagnosis risk, so it cannot prove that segregation causes dementia or that any treatment would change this risk.
-
46/100
Among 738 MA and 1488 FFS participants, weighted mean age was 76 years (SD 7.0), 59% were female, and 9% had probable dementia.
Why it matters
This study found that Medicare Advantage enrollees were less likely to report improved function during rehabilitation than fee-for-service beneficiaries, but there were no significant differences in annual changes in physical performance or function. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
PLWD proactively enrolled in a dementia care program have high baseline rates of behavioral issues and their caregivers have elevated depression and stress scores.
Why it matters
In a value-based Medicare Advantage population, 195 of eligible patients (33.1%) enrolled in a dementia care coordination program in which a nurse practitioner assessed needs and shared care plans with primary care providers. This is an early report on program enrollment and care coordination, not on treating, curing or preventing Alzheimer's disease.
-
Participants identified as non-Hispanic White (50%), non-Hispanic Black (30%), or Hispanic (13%).
Why it matters
In this cross-sectional study of people living with dementia receiving home health services, neuropsychiatric symptoms were prevalent in 97% of participants and increased with dementia severity, with few differences by racial and ethnic group. The authors call for better methods to identify, assess, and manage these symptoms in homebound people with dementia, which is about symptom care rather than treating, curing, or preventing the disease.
-
Language impairment is an important biomarker of neurodegenerative disorders such as Alzheimer's disease (AD).
Why it matters
This study showed that a large language model could use transcribed speech to distinguish people with Alzheimer's disease from healthy controls and estimate cognitive test scores. It is a diagnostic approach and does not test any treatment, cure, or prevention.
-
An increasing number of older adults reside in assisted living (AL) toward the end of life, and it remains unclear if this trend represents an additional place of care and end-of-life transition before eventual nursing home admission.
Why it matters
This study describes assisted living residents who died during follow-up, finding that most had Alzheimer's disease and related dementia and that half died in assisted living. It is about end-of-life care settings and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
This Viewpoint discusses the potential benefits and harms of prior authorization in Medicare Advantage and the health policy implications and opportunities for improvement.
Why it matters
This viewpoint discusses the potential benefits and harms of prior authorization in Medicare Advantage and opportunities for improvement. It contains no research findings on treating, curing, or preventing Alzheimer's disease.
-
There were 115,757 NH residents with dementia who self-reported pain in the last 30 days of life.
Why it matters
This study found that among nursing home residents with dementia who died with pain, pain affected quality of life in more than one in five, with small differences by Medicare payment model. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
46/100
Over the next 25 years, the prevalence of dementia in people older than 65 years is projected to exceed 25% nationwide, including metropolitan areas.
Why it matters
This study projected future dementia prevalence in Japan using data from the Toyama Dementia Survey, estimating that prevalence would exceed 20% nationwide by 2030 and 25% in 42 prefectures by 2035. It is a prevalence projection and provides no evidence on treating, curing, or preventing Alzheimer's disease.
-
On 7 June 2021, aducanumab was granted accelerated approval for the treatment of Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering effects considered reasonably likely to confer clinical benefit.
Why it matters
This article discusses the FDA's 2021 accelerated approval of aducanumab based on amyloid-lowering effects considered reasonably likely to confer clinical benefit, and notes that many questioned how the evidence and patients' best interests were weighed. It raises doubts about the approval rather than showing that aducanumab cures or prevents Alzheimer disease.
-
To determine the risk for dementia in neurofibromatosis type 1 (NF1) using a Finnish nationwide cohort of individuals with NF1, and data from national registries.
Why it matters
In a Finnish nationwide cohort, people with neurofibromatosis type 1 had an increased risk of Alzheimer disease compared with controls. This identifies a risk association only and does not test any treatment, cure, or prevention.
-
The rate of hospital admissions are variable between GP practices, with deprivation and being admitted from home as risk factors for admission for ACSC and non-ACSC admissions.
Why it matters
This ecological analysis found that hospital admission rates for people living with dementia varied between GP practices in England, with deprivation and being admitted from home as risk factors, and the mental health budget allocated by the CCG showed diverging effects for avoidable versus non-avoidable admissions. The authors suggest there is potential scope for improvement in services, but this is about avoidable hospital admissions, not treating, curing, or preventing dementia.
-
Having a LOC HI aged 50's and younger was linked with lower later-life cognitive function at age ~70 than expected.
Why it matters
In 502 people from a British birth cohort, head injury with loss of consciousness more than 15 years earlier was linked to worse cognitive test performance, partly explained by smaller brain volume and white matter changes. The study found no evidence that such head injury was associated with amyloid load, hippocampal volume, or other Alzheimer's-related markers.
-
All groups showed a worsening of cognitive (39.6%), pre-existing (37.5%), and new (26%) behavioral symptoms, and motor symptoms (35.4%) during the COVID-19 lockdown, resulting in an increased caregiver burden in 26% of cases.
Why it matters
This study found that during the COVID-19 lockdown, people with Parkinson's disease and mild cognitive impairment showed worsening cognitive, behavioral, and motor symptoms, with increased caregiver burden. It describes the impact of quarantine on symptoms and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Occupational noise exposure accounts for approximately 16% of all disabling hearing losses, but the true value and societal costs may be grossly underestimated because current regulations only identify hearing impairments in the workplace if exposures result in audiometric threshold shifts within a limited frequency region.
Why it matters
This review notes that hearing loss, including from occupational noise, is a risk factor for dementia among other disorders. It discusses noise regulations and does not report any treatment, cure, or prevention for Alzheimer's disease.
-
It is a piece of evidence that cognitive dysfunction, even in early stage of memory decline, may have some bad impact on balance and gait regardless of the effect of musculoskeletal problems.
Why it matters
Among 30 healthy controls, 30 people with mild cognitive impairment and 30 with mild dementia due to Alzheimer's disease, balance and gait measures differed significantly across groups, with balance in mild dementia worse than in mild cognitive impairment. This prospective observational study describes physical performance and does not test treating, curing or preventing Alzheimer's disease.
-
We examined state variations in assisted living (AL) regulatory policies for admission/retention, staffing/training, medication management, and dementia care.
Why it matters
This study found significant variation between US states in the strictness of assisted living regulations covering admission, staffing, medication management and dementia care. It concerns regulation of care settings, not the treatment, cure or prevention of Alzheimer's disease itself.
-
The Medicare annual wellness visit-a preventive care visit free to Medicare beneficiaries enrolled in Part B-requires detection of cognitive impairment.
Why it matters
This survey found that about half of Medicare beneficiaries had an annual wellness visit, but fewer than one-third received a structured cognitive assessment. Medicare Advantage enrollees were more likely than fee-for-service enrollees to have both an annual wellness visit and a structured cognitive assessment.
-
46/100
COVID-19 pandemic and the lockdown produced psychological consequences in caregivers of pwD, with an increase of levels of depression.
Why it matters
This survey of 84 Italian caregivers of people with dementia found that depression increased during the COVID-19 lockdown, and that caregivers with high resilience showed a larger increase in anxiety than those with low resilience. It is about caregiver psychological effects and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Mild cognitive impairment (MCI) can be an indicator representing the early stage of Alzheimier's disease (AD).
Why it matters
This study developed a machine learning framework using resting-state EEG signals that distinguished patients with mild cognitive impairment from healthy controls with high classification accuracy. It is about detection of mild cognitive impairment, not about treating, curing, or preventing Alzheimer's disease.
-
COVID-19 pandemic in Argentina has affected the care of older adults with dementia deeply.
Why it matters
This survey of 80 family caregivers in Argentina found that COVID-19 confinement increased caregiver stress regardless of the dementia stage, with more stress among those caring for severe cases. It is about caregiver experience during the pandemic and does not test any treatment for dementia.
-
These data suggest that current treatment of late stage parkinsonism in the community remains insufficiently effective to alleviate disabling symptoms in many patients.
Why it matters
This study of late-stage parkinsonism found that dementia was present in 37% of patients and that current treatment remains insufficiently effective to alleviate disabling symptoms in many patients. It concerns Parkinson's disease management, not treating, curing, or preventing Alzheimer's disease.
-
This research indicates that diet and exercise programs have the potential to improve aspects of cognition and mood in an aging population.
Why it matters
In this 6-month pilot study of 102 older people, there was no significant change in overall memory, though the combined diet and exercise group improved on spatial working memory and emotional state. These are early, limited findings about lifestyle and cognition, not evidence of treating, curing, or preventing Alzheimer's disease.
-
Despite the extended study duration, participants demonstrated high compliance with the schedule of daily learning tasks and were extremely positive about their experiences.
Why it matters
In 35 adults aged 40 to 59 with no diagnosis of cognitive impairment, participants complied with 80% of daily learning tasks in the Mezurio smartphone app over up to 36 days, with 88% still engaged by the final task. This shows that frequent remote cognitive assessment is feasible, but it does not test any treatment, cure or prevention.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Association between metabolic syndrome and risk of incident dementia in UK Biobank
- Small Area Estimation under Spatial Multivariate Fay–Herriot Model
- Association of Dual-Task Gait With Incident Dementia in Mild Cognitive Impairment: Results From the Gait and Brain Study
- Association Between Poor Cognitive Functioning and Risk of Incident Parkinsonism: The Rotterdam Study
- Functional levels and nurse workload of elderly awaiting nursing home placement and nursing home residents: a comparative study
- Domain-specific physical activity levels and risk of dementia: a systematic review and meta-analysis
- Psychiatric illness and mortality after hip fracture
- Relationship Between Sedentary Lifestyle, Physical Activity and Stress in University Students and Their Life Habits: A Scoping Review with PRISMA Checklist (PRISMA-ScR)
- Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI?
- Effect of a multicomponent exercise programme (VIVIFRAIL) on functional capacity in frail community elders with cognitive decline: study protocol for a randomized multicentre control trial